Search results for "HRA"
showing 10 items of 1703 documents
CCDC 689511: Experimental Crystal Structure Determination
2009
Related Article: A.Bogdan, M.Bolte, V.Bohmer|2008|Chem.-Eur.J.|14|8514|doi:10.1002/chem.200801268
CCDC 1912382: Experimental Crystal Structure Determination
2019
Related Article: Javier Pitarch-Jarque, Kari Rissanen, Santiago García-Granda, Alberto Lopera, M. Paz Clares, Enrique García-España, Salvador Blasco|2019|New J.Chem.|43|18915|doi:10.1039/C9NJ05231C
CCDC 152579: Experimental Crystal Structure Determination
2001
Related Article: M.J.Krische, J.-M.Lehn, N.Kyritsakas, J.Fischer, E.K.Wegelius, K.Rissanen|2000|Tetrahedron|56|6701|doi:10.1016/S0040-4020(00)00489-0
A subset of flavaglines inhibits KRAS nanoclustering and activation.
2020
The RAS oncogenes are frequently mutated in human cancers and among the three isoforms (KRAS, HRAS and NRAS), KRAS is the most frequently mutated oncogene. Here, we demonstrate that a subset of flavaglines, a class of natural anti-tumour drugs and chemical ligands of prohibitins, inhibit RAS GTP loading and oncogene activation in cells at nanomolar concentrations. Treatment with rocaglamide, the first discovered flavagline, inhibited the nanoclustering of KRAS, but not HRAS and NRAS, at specific phospholipid-enriched plasma membrane domains. We further demonstrate that plasma membrane-associated prohibitins directly interact with KRAS, phosphatidylserine and phosphatidic acid, and these int…
Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycl…
2009
Background The prevalence of and risk factors for central nervous system recurrence in patients with acute promyelocytic leukemia are not well established and remain a controversial matter. Design and Methods Between 1996 and 2005, 739 patients with newly diagnosed acute promyelocytic leukemia enrolled in two consecutive trials (PETHEMA LPA96 and LPA99) received induction therapy-with all-trans retinoic acid and idarubicin. Consolidation therapy comprised three courses of anthracycline monochemotherapy (LPA96), with all-trans retinoic acid and reinforced doses of idarubicin in patients with an intermediate or high risk of relapse (LPA99). Central nervous system prophylaxis was not given. Re…
Urethral Stricture Formation Following Cuff Erosion of AMS Artificial Urinary Sphincter Devices: Implication for a Less Invasive Explantation Approach
2022
ObjectivesThe objective of this study is to describe a standardized less invasive approach in patients with artificial urinary sphincter (AUS) explantation due to cuff erosion and analyze success and urethral stricture rates out of a prospective database. Evidence regarding complication management is sparse with heterogenous results revealing high risk of urethral stricture formation despite simultaneous urethroplasty in case of AUS explantation.Patients and MethodsData of all patients undergoing AUS implantation due to stress urinary incontinence (SUI) in our tertiary center were prospectively collected from 2009 to 2015. In case of cuff erosion, AUS explantation was carried out in an inst…
Epidemiology of congenital diaphragmatic hernia in Europe: a register-based study.
2015
INTRODUCTION: Published prevalence rates of congenital diaphragmatic hernia (CDH) vary. This study aims to describe the epidemiology of CDH using data from high-quality, population-based registers belonging to the European Surveillance of Congenital Anomalies (EUROCAT).METHODS: Cases of CDH delivered between 1980 and 2009 notified to 31 EUROCAT registers formed the population-based case series. Prevalence over time was estimated using multilevel Poisson regression, and heterogeneity between registers was evaluated from the random component of the intercept.RESULTS: There were 3373 CDH cases reported among 12 155 491 registered births. Of 3131 singleton cases, 353 (10.4%) were associated wit…
"Figure 4.2.0" of "Measurement of the higher-order anisotropic flow coefficients for identified hadrons in Au$+$Au collisions at $\sqrt{s_{_{NN}}}$ =…
2021
Radial flow rapidity anisotropy $\rho_n$ in the blast-wave model fit to azimuthal anisotropy $v_2$ and invariant yields in Au+Au collisions at $\sqrt{s_{NN}} =$ 200 GeV.
"Figure 4.1" of "Measurement of the higher-order anisotropic flow coefficients for identified hadrons in Au$+$Au collisions at $\sqrt{s_{_{NN}}}$ = 2…
2021
Radially averaged flow rapidity $$ in the blast-wave model fit to azimuthal anisotropy and invariant yields in Au+Au collisions at $\sqrt{s_{NN}} =$ 200 GeV.
"Figure 4.2.3" of "Measurement of the higher-order anisotropic flow coefficients for identified hadrons in Au$+$Au collisions at $\sqrt{s_{_{NN}}}$ =…
2021
Radial flow rapidity anisotropy $\rho_n$ in the blast-wave model fit to azimuthal anisotropy $v_4\{\Psi_2\}$ and invariant yields in Au+Au collisions at $\sqrt{s_{NN}} =$ 200 GeV.